Direxion Healthcare Bull 3X

National Advertising Review Board Refers Merck's Bravecto Dose Claim to FTC and FDA

Eli Lilly Acquires Engage Bio to Accelerate Non-Viral Gene Drug Development

Merck and Kailun Bio's Sac-TMT Succeeds in Phase III Endometrial Cancer Trial

CDD and Eli Lilly Collaborate to Integrate TuneLab AI Platform into CDD Vault

Trump Portfolio Precisely Trades UnitedHealth Before Medicare Policy Reversal

Fideuram Intesa Sanpaolo Acquires 84,300 JNJ Shares Worth $17.4M in Q4

Eli Lilly and Company announces an additional $4.5 billion investment in its Indiana manufacturing sites

Eli Lilly and Novo Nordisk are preparing to launch high-dose obesity treatments in the South Korean market

Financial disclosure reveals Donald Trump invested in Eli Lilly in Q1 2026, coinciding with the government's push for favorable weight-loss drug policies.

UnitedHealth Group Faces Profit Pressure Amid Rising Medical Costs and Membership Structure Changes

Eli Lilly Completes Key Drug Interaction Study for its KRAS Inhibitor, Olomorasib

New report shows Eli Lilly and Novo Nordisk dominate GLP-1 drug citations in AI tools

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

Canada Approves Generic Version of Novo Nordisk's Ozempic, Potentially an Indirect Positive for Lilly

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

BiomX

Vida Global

MicroAlgo

MetaVia

Tradr 2X Long XNDU Daily ETF

CURE

Michael Burry has invested in Pfizer, Molina Healthcare, and Halliburton, citing their earnings stability and inflation resilience. Pfizer provides a high dividend and strong drug pipeline, Molina is expected to recover, and Halliburton benefits from rising oil prices. However, a potential recession poses risks, although current valuations suggest limited downside.

- Michael Burry has invested in Pfizer, Molina Healthcare, and Halliburton due to their earnings stability, pricing power, and resilience against inflation.  
- Pfizer is noted for its high dividend and strong drug pipeline, Molina is expected to rebound after a challenging year, and Halliburton benefits from the recovery in oil prices.  
- While a recession could impact these stocks, their current valuations suggest that significant downside risk is already priced in.

Pfizer

Molina Healthcare

Halliburton

iShares US Oil Equip & Svcs

SPDR O&G Equip

iShares US Pharma

VanEck Oil Services ETF

Health Care Select Sector SPDR

iShares US Healthcare Providers

SPDR O&G Ex & Prd

iShares Global Healthcare

VG Health

Michael Burry targets Pfizer, Molina, Halliburton as inflation hedge

Molina Healthcare Inc. (MOH) shares rose 3.45% to $191.58 on Tuesday, ending a three-day losing streak, despite underperforming compared to competitors like Humana Inc. and Centene Corp., which saw gains of 7.69% and 5.23%, respectively. The stock remains 41.53% below its 52-week high of $327.68 reached on May 20. Trading volume was 954,383, significantly below the 50-day average of 1.6 million shares.

MarketWatch Automated

ProShares Ultra Health Care ETF

SPDR S&P Health

Dow Jones Industrial Average

S&P 500

Humana

Centene

Factset Research

Molina Healthcare Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

SNDA

ERAS

Healthcare stocks showed mixed performance on May 11, 2026, with the NYSE Healthcare Index up 0.2%. Moderna's shares fell 2.2% as it works on early-stage hantavirus vaccines. Sonida Senior Living reported a Q1 loss of $2.39 per share, leading to a 3.6% drop in its stock. In contrast, Erasca's shares rose 3.3% after announcing a collaboration with Merck for a clinical trial, while Merck's stock increased by 1.2%.

Fidelity

Sonida Senior Living

Erasca

Merck

Invesco Biotechnology & Genome ETF

Fidelity MSCI Health Care Index

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Health Equip

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

iShares US Medical Devices

SPDR S&P Biotech

iShares Biotechnology ETF

Moderna

Sector Update: Healthcare Stocks Mixed in Afternoon Trading

RSPH

Molina Healthcare shareholders approved governance and bylaw changes at the May 6, 2026 annual meeting. Key amendments allow stockholders with at least 20% voting power to call special meetings. The board adopted new bylaws detailing procedural safeguards. Shareholders elected ten directors, ratified Ernst & Young as auditor, and increased shares under the 2025 Equity Incentive Plan. The latest analyst rating for MOH stock is a Buy with a $250 price target, though concerns about recent fundamentals and valuation persist. Molina Healthcare focuses on providing health insurance to low-income populations.

Tip Ranks

Invesco S&P 500 Equal Weight Health Care ETF

Molina Healthcare Shareholders Approve Governance and Bylaw Changes

Centric Wealth Management has reduced its stake in Molina Healthcare, Inc (NYSE:MOH) by 74.3%, now holding 3,100 shares valued at $562,000. Other institutional investors have also adjusted their positions in the company. Molina Healthcare's stock opened at $186.07, with a market cap of $9.69 billion and a PE ratio of 55.05. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and an average price target of $169.60. The company specializes in government-sponsored health insurance programs.

Market Beat

Rakuten Group, Inc.

Mizuho Financial Group, Inc.

Mizuho Financial

Deutsche Bank AG

Goldman Sachs

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

GS Hldg R

Centric Wealth Management Cuts Stock Position in Molina Healthcare, Inc $MOH

Molina Healthcare Inc. (MOH) shares fell 3.08% to $185.94 on Friday, marking its second consecutive day of losses, despite a positive trading session for the stock market. The S&P 500 rose 0.84%, while Molina's stock is now 44.16% below its 52-week high of $333.00. In contrast, competitors Humana Inc. and Centene Corp. saw gains of 11.27% and 1.78%, respectively. Trading volume was 1.5 million, below the 50-day average of 1.6 million.

Molina Healthcare Inc. Stock Underperforms Friday When Compared To Competitors

CUBT

Biocure Technology Inc. has announced the adoption of semi-annual financial reporting under Coordinated Blanket Order 51-933. This change exempts the company from filing quarterly interim financial statements, as it meets the eligibility criteria of being a venture issuer with annual revenues under $10 million. Biocure will not file interim financial statements for the period ending March 31, 2026, but will continue to submit audited annual financial statements and six-month interim reports. The company remains committed to timely disclosure of material changes as required by regulations.

TheNewswire

Curative Biotechnology, Inc.

Biocure Technology Inc. Announces Adoption of Semi-Annual Reporting

Molina Healthcare recently held its Investor Day Conference, outlining long-term financial targets and strategic plans for growth in its Medicaid, Medicare, and Marketplace businesses. The company emphasized AI initiatives and capital allocation while warning of regulatory and execution risks affecting its 2029 outlook. Analysts rate MOH stock as a Buy with a $250 target, though Spark's AI Analyst considers it Neutral due to recent revenue and margin pressures. Molina Healthcare focuses on government-sponsored health insurance for low-income and vulnerable populations, with a current market cap of $10B.

Molina Healthcare Unveils Long-Term Strategy at Investor Day

Molina Healthcare will host an Investor Day on May 8, 2026, at 9:30 a.m. ET to discuss long-term financial targets and strategic plans. The event will include a live webcast and a 30-day online replay. Presentation materials will be available, containing forward-looking statements regarding 2029 performance, premium revenue, and adjusted EPS targets, which are subject to risks. This information is part of an SEC filing.

TradingView

Molina to hold May 8 Investor Day outlining 2029 targets, strategic plans and webcast access

Molina Healthcare Inc. (MOH) shares fell 2.83% to $191.85 on Thursday, underperforming compared to competitors like Humana Inc. (HUM), which rose 0.32%, and Centene Corp. (CNC), which fell 0.63%. The S&P 500 Index and Dow Jones Industrial Average also declined by 0.38% and 0.63%, respectively. Molina's stock is currently 42.39% below its 52-week high of $333.00 reached on May 12th, with trading volume at 738,662, significantly below the 50-day average of 1.6 million shares.

Molina Healthcare Inc. Stock Underperforms Thursday When Compared To Competitors

Direxion Healthcare Bull 3X(CURE.US)